medigraphic.com
ISSN 1527-3172 (Electronic)

2010, Number 1

<< Back Next >>

MEDICC Review 2010; 12 (1)

Clinical development and perspectives of CIMAvax EGF, cuban vaccine for non-small-cell lung cancer therapy

Rodríguez PC, Rodríguez G, González G, Lage A

Language: English
References: 51
Page: 17-23
PDF size: 149.80 Kb.


ABSTRACT

Introduction CIMAvax EGF is a therapeutic anticancer vaccine developed entirely in Cuba and licensed in Cuba for use in adult patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). The vaccine is based on active immunotherapy by which an individual’s immune response is manipulated to release its own effector antibodies (Abs) against the epidermal growth factor (EGF).
Objective Review pre-clinical and clinical research conducted during development of CIMAvax EGF, primarily studies published by Cuban investigators in international peer-reviewed scientific journals.
Methods An automated search for “vaccine” and “EGF” was conducted in PubMed, resulting in 17 articles published by Cuban authors between January 1, 1994 and September 30, 2009. Main findings were described and discussed, along with unpublished preliminary findings of an initial ongoing phase III clinical trial.
Results Articles reviewed describe five phase I/II and one phase II clinical trials conducted in Cuba in 1995–2005. A non-controlled 1995–1996 study resulted in the earliest published scientific evidence of the feasibility of inducing an immune response against autologous EGF in patients with different advanced stage tumors. Subsequent controlled, randomized trials included patients with advanced stage (IIIB/IV) NSCLC. The 2nd and 3rd phase I/II trials differentiated immunized patients as poor antibody responders (PAR) and good antibody responders (GAR), according to their anti-EGF antibody response, and confirmed greater immunogenicity with Montanide ISA 51 adjuvant in the vaccine formulation, as well as the benefits of low-dose cyclophosphamide treatment 72 hours before the first immunization. The 4th phase I/II trial found increased immunogenicity with an increased dose divided in 2 anatomical sites and also established correlation between Ab titers, serum EGF concentration and length of survival. In the first 4 phase I/II trials and the phase II trial, vaccine was administered after chemotherapy (ChTVV schedule). In the 5th phase I/II trial, longer survival and increased immunogenicity were achieved using a VChTV schedule and dividing the vaccine dose in 4 anatomical sites. The phase II clinical trial confirmed results of earlier studies as well as the mildto- moderate adverse event profile associated with CIMAvax EGF. Longer survival was observed in all vaccinated patients compared to controls, and the difference was significant (p ‹0.05) in the group aged ‹ 60 years.
Conclusions CIMAvax EGF’s benefits in earlier NSCLC stages and in other tumor locations, as well as in patients unfit for chemotherapy, need to be evaluated. Evidence of the vaccine’s safety for chronic use also needs to be systemized.


REFERENCES

  1. Galán Y, Fernández L, Torres P, García M. Trends in Cuba’s Cancer Incidence (1990 to 2003) and Mortality (1990 to 2007). MEDICC Review. 2009;11(3):19–26.

  2. Romero T. Changing the Paradigm of Cancer Control in Cuba. MEDICC Review. 2009;11(3):5–7.

  3. Lage A. Connecting immunology research to public health: Cuban biotechnology. Nature Immunology. 2008;9(2):109–12.

  4. Lage A. Transforming Cancer Indicators Begs Bold New Strategies from Biotechnology. MEDICC Review. 2009;11(3):8–12.

  5. Gerard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for nonsmall cell lung cancer. Mol Oncol. 2009 Dec;3(5– 6):409–24.

  6. Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007 Jan–Mar;22(1 Suppl 4):S24–39.

  7. Hirsch FR, Varella-García M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 2009 Aug;28 Suppl 1:S32–7.

  8. González G, Lage A. Cancer Vaccines for Hormone/ Growth Factor Immune Deprivation: A Feasible Approach for Cancer Treatment. Curr Cancer Drug Targets. 2007 May;7(3):229–41.

  9. Macías A, Azavedo E, Hägerström T, Klintenberg C, Pérez R, Skoog L. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinoma. Anticancer Res. 1987 May–Jun;7(3 Pt B):459–64.

  10. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003 Mar 10;284(1):122–30.

  11. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003;35(5):327–36.

  12. Pérez R, Pascual M, Macías A, Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1984 Sep;4(3):189–93.

  13. González G, Sánchez B, Suárez E, Beausoleil I, Perez O, Lastre M, et al. Induction of immune recognition of self-epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vac Res. 1996;5(4):233–44.

  14. González G, Pardo OL, Sánchez B, García JL, Beausoleil I, Marinello P, et al. Induction of immune recognition of self-epidermal growth factor II: characterization of the antibody immune response and the use of a fusion protein. Vac Res. 1997;6(2):91–100.

  15. González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol. 1998 Apr;9(4):431–5.

  16. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. J Clin Oncol. 2008 Jul 10;26(20):3351–7.

  17. González G, Crombet T, Torres F, Catalá M, Alfonso L, Osorio M, et al. Epidermal growth factorbased cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol. 2003 Mar;14(3):461–6.

  18. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004 Feb;34(2):336–44.

  19. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002 May 15;62(10):2731–5.

  20. González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin. 2007 Jan–Feb;3(1):8–13.

  21. Crombet T, Neninger E, Catalá M, García B, Leonard I, Martínez L, et al. Treatment of NSCLC Patients with an EGF-Based Cancer Vaccine: report of a Phase I trial. Cancer Biol Ther. 2006 Feb;5(2):130–40.

  22. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1;22(3):403–15.

  23. Gardiner DF, Huang Y, Basu S, Leung L, Song Y, Chen Z, et al. Multiple-site DNA vaccination enhances immune responses in mice. Vaccine. 2006 Jan 16;24(3):287–92.

  24. Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine. 2006 Apr 12;24 Suppl 2:S2–44–5.

  25. Lage A, Pérez R, Fernández LE. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets. 2005 Dec;5(8):611–27.

  26. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science. 2001 Jul 13;293(5528):251–3.

  27. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med. 1998 Dec 24;339(26):1905–13.

  28. Couch M, Saunders JK, O’Malley BW Jr, Pardoll D, Jaffee E. Spatial distribution of tumor vaccine improves efficacy. Laryngoscope. 2003 Aug;113(8):1401–5.

  29. Rodríguez PC, González I, González A, Avellanet J, López A, Pérez R, et al. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine. Vaccine. 2008 Aug 26;26(36):4647–54.

  30. Hanahan D, Weinberg RA. The Hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70. Review.

  31. Dunn GP, Old LJ, Schreiber RD. The Three Es of Cancer Immunoediting. Annu Rev Immunol. 2004;22:329–60.

  32. Kroemer G, Pouyssegur J. Tumor Cell Metabolism: Cancer’s Achilles’ Heel. Cancer Cell. 2008 Jun;13(6):472–82. Review.

  33. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436–44. Review.

  34. Mantovani A. Inflaming Metastasis. Nature. 2009 Jan 1;457(7225):36–7.

  35. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with citotoxic chemotherapy. Cancer Res. 2005 Sep 15;65(18):8059–64.

  36. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007 Aug;56(8):2715–8.

  37. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007 Nov;13(11):1365–8.

  38. Terando A, Mulé JJ. On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother. 2003 Nov;52(11):680–5.

  39. Ehrke MJ. Immunomodulation in cancer therapeutics. Int Immunopharmacol. 2003 Aug;3(8):1105–19. Review.

  40. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol. 1982 Jun;128(6):2453–7.

  41. Sinkovics JG, Horvath JC. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol. 2006 Oct;29(4):765–77.

  42. Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, et al. Combining an EGFbased cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother. 2009 Jan;32(1):92–9.

  43. Montero E, Valdés M, Avellanet J, López A, Pérez R, Lage A. Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Vaccine. 2009 Apr 6;27(16):2230–9.

  44. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced NSCLC. J Clin Oncol. 2008 Mar 20;26(9):1452–8.

  45. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, et al. Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti-Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine. Clin Cancer Res. 2008 Feb 1;14(3):840–6.

  46. CIMAvax EGF® Conjugado químico de Factor de Crecimiento Epidérmico humano recombinante acoplado a la proteína recombinante rP64K, Número de Registro B- 08- 063- L03- C, Centro de Inmunología Molecular (CIM), Cuba. Centro para el Control de la Calidad de los Medicamentes (CECMED). Havana, Cuba; 2008 June 12.

  47. Rodríguez G, González G, Crombet T, Lage A. CIMAvax EGF Development and Manufacturing. Biopharm International. 2008 Oct;Suppl 1:S36–42.

  48. Schlom J, Arlen PM, Gulley JL. Cancer Vaccines: Moving Beyond Current Paradigms. Clin Cancer Res. 2007 Jul 1;13(13):3776–82.

  49. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al. A Clinical Development Paradigm for Cancer Vaccines and Related Biologics. J Immunother. 2007 Jan;30(1):1–15.

  50. Fine GD. Consequences of delayed treatment effects on analysis of time-to-event endpoints. Drug Inf J. 2007;41(4):535–9.

  51. Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castrationresistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther. 2009 Oct 27;10(1):1–10.




2020     |     www.medigraphic.com